Head-to-head evidence
risankizumab vs ustekinumab-stba (Steqeyma)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
risankizumab · Skyrizi
Marketed by AbbVie
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
ustekinumab-stba (Steqeyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
risankizumab · Skyrizi
Marketed by AbbVie
NCT03104413 · Phase 3 · completed
Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.
Next expected readout: March 2027 · NCT06063967 (registry estimate)
ustekinumab-stba (Steqeyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · ustekinumab-stba (Steqeyma)'s landscape